Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial

Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results... Am J Cardiovasc Drugs (2016) 16:55–65 DOI 10.1007/s40256-015-0146-z OR IGINAL RESEARCH ARTIC L E Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial 1 2 2 3 • • • • Stephen J. Nicholls Rishi Puri Kathy Wolski Christie M. Ballantyne 4 5 6 2 • • • • Philip J. Barter H. Bryan Brewer John J. P. Kastelein Bo Hu 2 1 7 8 • • • • Kiyoko Uno Yu Kataoka Jean-Paul R. Herrman Bela Merkely 2 2 Marilyn Borgman Steven E. Nissen Published online: 18 September 2015 Springer International Publishing Switzerland 2015 Abstract baseline) and 12.8 % with RVX-208 (P\ 0.001 compared Background Bromodomain and extra-terminal (BET) with baseline), between groups P = 0.18. HDL-C increased proteins regulate transcription of lipoprotein and inflam- by 9.1 % with placebo (P\ 0.001 compared with baseline) matory factors implicated in atherosclerosis. The impact of and 11.1 % with RVX-208 (P\ 0.001 compared with BET inhibition on atherosclerosis progression is unknown. baseline), between groups P = 0.24. Low-density lipoprotein Methods ASSURE was a double-blind, randomized, cholesterol (LDL-C) decreased by 17.9 % with placebo multicenter trial in which http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cardiovascular Drugs Springer Journals

Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial

Loading next page...
 
/lp/springer-journals/effect-of-the-bet-protein-inhibitor-rvx-208-on-progression-of-coronary-oA9k58LvSm

References (30)

Publisher
Springer Journals
Copyright
Copyright © 2015 by Springer International Publishing Switzerland
Subject
Medicine & Public Health; Cardiology; Pharmacotherapy; Pharmacology/Toxicology
ISSN
1175-3277
eISSN
1179-187X
DOI
10.1007/s40256-015-0146-z
pmid
26385396
Publisher site
See Article on Publisher Site

Abstract

Am J Cardiovasc Drugs (2016) 16:55–65 DOI 10.1007/s40256-015-0146-z OR IGINAL RESEARCH ARTIC L E Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial 1 2 2 3 • • • • Stephen J. Nicholls Rishi Puri Kathy Wolski Christie M. Ballantyne 4 5 6 2 • • • • Philip J. Barter H. Bryan Brewer John J. P. Kastelein Bo Hu 2 1 7 8 • • • • Kiyoko Uno Yu Kataoka Jean-Paul R. Herrman Bela Merkely 2 2 Marilyn Borgman Steven E. Nissen Published online: 18 September 2015 Springer International Publishing Switzerland 2015 Abstract baseline) and 12.8 % with RVX-208 (P\ 0.001 compared Background Bromodomain and extra-terminal (BET) with baseline), between groups P = 0.18. HDL-C increased proteins regulate transcription of lipoprotein and inflam- by 9.1 % with placebo (P\ 0.001 compared with baseline) matory factors implicated in atherosclerosis. The impact of and 11.1 % with RVX-208 (P\ 0.001 compared with BET inhibition on atherosclerosis progression is unknown. baseline), between groups P = 0.24. Low-density lipoprotein Methods ASSURE was a double-blind, randomized, cholesterol (LDL-C) decreased by 17.9 % with placebo multicenter trial in which

Journal

American Journal of Cardiovascular DrugsSpringer Journals

Published: Sep 18, 2015

There are no references for this article.